Patents Assigned to Alkermes Controlled Therapeutics, Inc.
-
Patent number: 5922253Abstract: The present invention relates to a method for forming microparticles of a material from microdroplets of a solution, wherein the solution comprises the material dissolved in a solvent. The method includes the steps of directing the microdroplets into a freezing zone, whereby the microdroplets freeze. The frozen microdroplets are then contacted with a liquid non-solvent to extract the solvent into the non-solvent, thereby forming the microparticles.Type: GrantFiled: May 18, 1995Date of Patent: July 13, 1999Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Paul F. Herbert, Michael S. Healy
-
Patent number: 5916597Abstract: Composition for the sustained release of a biologically active agent in vivo. The composition comprises microcarriers containing a first solid-phase biocompatible material and a biologically active agent, wherein said microcarriers sustain the in vivo release of the biologically active agent. The composition also contains particles of a second biocompatible solid-phase material wherein the second solid-phase material further sustains the in vivo release of the biologically active agent.The invention also relates to a method for sustaining effective serum levels of a biologically active agent in a subject, including forming an injectable dose containing an effective amount of a biologically active agent, wherein the agent is contained in a microcarrier, with a release-period sustaining amount of a solid-phase material. The method further includes administering the injectable dose to the subject.Type: GrantFiled: August 29, 1996Date of Patent: June 29, 1999Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Hye-Jung Lee, OluFunmi L. Johnson, Stephen E. Zale, Mark A. Tracy
-
Patent number: 5916598Abstract: A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymer, an active agent, and a solvent. An immiscible second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are immersed in a quench liquid that includes a quench medium and a quantity of the solvent. The quantity of the solvent is selected to control a rate of extraction of the solvent from the first phase. The first phase is isolated in the form of microparticles. Also disclosed is a microencapsulated active agent prepared by the method for preparing biodegradable, biocompatible microparticles.Type: GrantFiled: May 4, 1998Date of Patent: June 29, 1999Assignee: Alkermes Controlled Therapeutics Inc. IIInventors: Michael E. Rickey, J. Michael Ramstack, Danny H. Lewis
-
Patent number: 5912015Abstract: The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal cation component which is separately dispersed within the polymeric matrix, whereby the metal cation component modulates the release of the biologically active agent from the polymeric matrix. The present invention also relates to a method for modulating the release of a biologically active agent from a biocompatible polymeric matrix, comprising the steps of dissolving a biocompatible polymer in a solvent to form a polymer solution and also separately dispersing a metal cation component and a biologically active agent within the polymer solution.Type: GrantFiled: April 7, 1998Date of Patent: June 15, 1999Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Howard Bernstein, Yan Zhang, M. Amin Khan, Mark A. Tracy
-
Patent number: 5891478Abstract: The method of the invention for producing a composition for the sustained release of biologically active hGH includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, metal cation-stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles.Type: GrantFiled: March 2, 1998Date of Patent: April 6, 1999Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: OluFunmi Lily Johnson, Medha M. Ganmukhi, Howard Bernstein, Henry Auer, M. Amin Khan
-
Patent number: 5792477Abstract: A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymeric encapsulating binder, and an active agent having limited water solubility dissolved or dispersed in a solvent. An aqueous second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are separated. The discontinuous first phase is washed with water, or an aqueous solution of water and a solvent for residual solvent in the first phase, to reduce the level of residual solvent in the microparticles to less than about 2% by weight of the microparticles. Also disclosed are a microencapsulated drug prepared by the method for preparing biodegradable, biocompatible microparticles, and a pharmaceutical composition that includes biodegradable and biocompatible microparticles in a pharmaceutically acceptable carrier.Type: GrantFiled: May 2, 1997Date of Patent: August 11, 1998Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen PharmaceuticaInventors: Michael E. Rickey, J. Michael Ramstack, Danny H. Lewis, Jean Mesens
-
Patent number: 5770231Abstract: The instant invention is related to a sustained-release microparticle produced by dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase.Type: GrantFiled: February 28, 1997Date of Patent: June 23, 1998Assignees: Alkermes Controlled Therapeutics, Inc. II, Janssen PharmaceuticaInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Patent number: 5733566Abstract: A delivery system for providing antiparasitic agents to animals is provided and a method of treating parasitic infections in animals using such delivery systems is described. The delivery system is particularly useful for treatment with avermectins and milbemycins in lactide/glycolide polymeric matrices.Type: GrantFiled: October 30, 1995Date of Patent: March 31, 1998Assignee: Alkermes Controlled Therapeutics Inc. IIInventor: Danny H. Lewis
-
Patent number: 5711968Abstract: This invention relates to a composition, and method of forming said composition, for the controlled release of interferon. The controlled release composition of this invention comprises a biocompatible polymer and particles of metal cation-stabilized interferon, wherein the particles are dispersed within the biocompatible polymer.The method of the invention, for producing a composition for the controlled release of interferon, includes dissolving a polymer in a polymer solvent to form a polymer solution, dispersing particles of metal cation stabilized-interferon particles in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of the interferon particles.Type: GrantFiled: July 25, 1994Date of Patent: January 27, 1998Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Mark A. Tracy, Howard Bernstein, M. Amin Khan
-
Patent number: 5688801Abstract: A pharmaceutical composition comprising a biodegradable and biocompatible composition comprising a 1,2 benzazole within a polymeric matrix. The 1,2 benzazole composition, pharmaceutically acceptable acid addition salts thereof, are potent antagonists of a series of neurotransmitters, particularly serotonin and dopamine. A method of inhibiting both serotonergic overactivity and dopaminergic overstimulation in animals is provided by administration of a biodegradable and biocompatible microparticle composition comprising a 1,2 benzazole or a pharmaceutically acceptable acid addition salt thereof. A method of treating warm blooded animals suffering from psychotic disorders, and a method of preparing the biodegradable and biocompatible composition are also described.Type: GrantFiled: March 14, 1995Date of Patent: November 18, 1997Assignees: Janssen Pharmaceutica, Alkermes Controlled Therapeutics Inc. IIInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Patent number: 5686092Abstract: A delivery system for providing growth promoters to food animals is provided and a method of promoting growth in food animals using such delivery systems is described.Type: GrantFiled: January 27, 1995Date of Patent: November 11, 1997Assignee: Alkermes Controlled Therapeutics Inc. IIInventor: Danny H. Lewis
-
Patent number: 5679377Abstract: Biodegradable, protein microspheres for in vivo release of a biologically active agent, as well as agricultural and environmental applications. The microspheres can be administered orally, intravenously, or subcutaneously for subsequent release. By selecting particular size ranges and the specific protein used to form the microsphere, it is possible to target the microspheres to a cell types such as macrophages, or to effect localized absorption of the microspheres to regions such as the mucosal membranes of the mouth, gastrointestinal tract, or urogenital areas. Larger forms of the microspheres can also be made using standard techniques of the desirable degradation properties.Type: GrantFiled: June 17, 1994Date of Patent: October 21, 1997Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Howard Bernstein, Eric Morrel, Edith Mathiowitz, Kirsten Schwaller, Thomas R. Beck
-
Patent number: 5654008Abstract: A process for preparing biodegradable microparticles comprising a biodegradable polymeric binder and a biologically active agent. A first phase, comprising the active agent and the polymer, and a second phase are pumped through a static mixer into a quench liquid to form microparticles containing the active agent. Preferably, a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons, is used to dissolve or disperse the agent and dissolve the polymer.Type: GrantFiled: October 10, 1996Date of Patent: August 5, 1997Assignee: Alkermes Controlled Therapeutics Inc. IIInventors: Paul F. Herbert, Azar M. Hazrati
-
Patent number: 5650173Abstract: Disclosed herein is a process for preparing biodegradable microparticles comprising a biodegradable polymeric binder and a biologically active agent, wherein a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons, is used to dissolve or disperse the agent and dissolve the polymer. The solvent blend containing the agent and polymer is dispersed in an aqueous solution to form microdroplets. The resulting emulsion is then added to an extraction medium preferably containing at least one of the solvents of the blend, whereby the rate of extraction of each solvent is controlled, whereupon the biodegradable microparticles containing the biologically active agent are formed.Type: GrantFiled: October 3, 1996Date of Patent: July 22, 1997Assignee: Alkermes Controlled Therapeutics Inc. IIInventors: J. Michael Ramstack, Paul F. Herbert, Jan Strobel, Thomas J. Atkins
-
Patent number: 5643595Abstract: A delivery system for providing growth promoters to food animals is provided and a method of promoting growth in food animals using such delivery systems is described.Type: GrantFiled: January 27, 1995Date of Patent: July 1, 1997Assignee: Alkermes Controlled Therapeutics Inc. IIInventor: Danny H. Lewis
-
Patent number: 5413797Abstract: ACTH polymeric controlled release systems are described wherein the ACTH retains good biological activity and is released over an extended period of time following administration by injection. In the preferred embodiment, the ACTH polymeric microspheres are made using very cold temperatures to freeze the polymer-ACTH mixtures into polymeric microspheres with very high retention of biological activity and material. Sustained release of biologically active ACTH is achieved when the microspheres are tested in vitro, extending over a period of greater than one day to several months. Altered release can be achieved by inclusion of degradation modifiers, pore forming agents, and stabilizers of the ACTH.Type: GrantFiled: June 30, 1994Date of Patent: May 9, 1995Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: M. Amin Khan, Howard Bernstein
-
Patent number: 5271961Abstract: Protein microspheres are formed by phase separation in a non-solvent followed by solvent removal. The preferred proteins are prolamines, such as zein, that are hydrophobic, biodegradable, and can be modified proteolytically or chemically to endow them with desirable properties, such as a selected degradation rate. Composite microspheres can be prepared from a mixture of proteins or a mixture of proteins with one or more bioerodible polymeric materials, such as polylactides. Protein coatings can also be made. Compounds are readily incorporated into the microspheres for subsequent release. The process does not involve agents which degrade most labile proteins. The microspheres have a range of sizes and multiple applications, including drug delivery and delayed release of pesticides, fertilizers, and agents for environmental cleanup.Type: GrantFiled: June 23, 1992Date of Patent: December 21, 1993Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Edith Mathiowitz, Howard Bernstein, Eric Morrel, Kirsten Schwaller